Table 1.
Baseline characteristics of patients with advanced gastric cancer
| NanoString cohort | Kim cohort | |
| Total (n=48) | Total (n=61) | |
| Age (years) | 61.50 (27–76) | 57 (26–78) |
| Sex | ||
| Male (28, 58%) | Male (43, 70%) | |
| Female (20, 42%) | Female (18, 30%) | |
| Race | ||
| Asian (48, 100%) | Asian (61, 100%) | |
| Type of specimens | ||
| FFPE (28, 58%) | FFPE (0, 0%) | |
| Biopsy (20, 42%) | Biopsy (61, 100%) | |
| Clinical center | ||
| NFH (12, 25%) | Samsung Medical Center (61, 100%) | |
| SYSUCC (21, 44%) | ||
| GDPHCM (6, 13%) | ||
| TSAHSYSU (5, 10%) | ||
| TFAHSYSU (4, 8%) | ||
| Type of checkpoint inhibitors | ||
| Camrelizumab (12, 25%) | Pembrolizumab (61, 100%) | |
| Toripalimab (12, 25%) | Camrelizumab (0, 0%) | |
| Sintilimab (11, 23%) | Toripalimab (0, 0%) | |
| Nivolumab (9, 19%) | Sintilimab (0, 0%) | |
| Pembrolizumab (4, 8%) | Nivolumab (0, 0%) | |
| Regimen | ||
| Monotherapy (19, 40%) | Monotherapy (61, 100%) | |
| Combination (29, 60%) | Combination (0, 0%) | |
| Number of previous therapies | ||
| 0 | 11 (23%) | 0 (0%) |
| 1 | 23 (48%) | 32 (52.5%) |
| >=2 | 14 (29%) | 29 (47.5%) |
FFPE, formalin-fixed paraffin-embedded; GDPHCM, Guangdong Provincial Hospital of Chinese Medicine; NFH, Nanfang Hospital, Southern Medical University; SYSUCC, Sun Yat-sen University Cancer Center; TFAHSYSU, The First Affiliated Hospital of Sun Yat-sen University; TSAHSYSU, The Sixth Affiliated Hospital of Sun Yat-sen University.